SB 666 - Currently, no restrictions to access shall be imposed that preclude the availability of any individual atypical antipsychotic monotherapy for the treatment of certain disorders in MO HealthNet participants. Under this act, no such restrictions shall be imposed for any individual antipsychotic medication. Additionally, this act modifies current law regarding the MO HealthNet Division's requirements to issue a provider update regarding cost considerations when enumerating treatment and utilization principles, as well as repeals language regarding the Division's adherence to certain principles when implementing new policies and clinical edits for antipsychotic drugs.

This act is identical to HB 867 (2019).

SARAH HASKINS

Statutes affected:
Introduced (3020S.02): 208.226, 208.227

---

Senate Committee Minutes:
SENATE COMMITTEE MINUTES Bill No.: SB 666
Sponsor: White
Hearing Date: 3/11/2020


COMMITTEE: Health and Pensions

CHAIRMAN: Onder

DATE REFERRED: 1/22/2020 DATE HEARING REQUESTED: 1/22/2020



STAFF:
Sarah Haskins
Katie O'Brien
Theckla Spainhower


WITNESSES GIVING INFORMATION:



WITNESSES FOR:
Gena Terlizzi - NAMI Missouri- National Alliance on Mental Illness- Missouri Chapter
Denise Mills
Kathy Harness - Mental Health America of Eastern MO
Jeff Howell - Missouri State Medical Association
Daniel Landon - Missouri Hospital Associaiton
Randy Scherr - Missouri Psychiatric Physicians Association
Arnie Deinoff - State Public Advocate


WITNESSES AGAINST: